A Phase 2 interventional study of NAL ER and Placebo in Refractory Chronic Cough, sponsored by Trevi Therapeutics. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Trevi Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Chronic Cough with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Chronic Cough · Canada.
Among the 22 studies in Chronic Cough with a site in Canada, this one is the 12th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 2, and was the 22nd registered.
142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.
Browse Chronic Cough studies →7 of the 22 studies in Chronic Cough with a site in Canada are open now. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18+ · Healthy volunteers
McMaster University · Sites in Canada
Ages 18+ · Healthy volunteers
McMaster University · Sites in Canada
Ages 18+
McMaster University · Sites in Canada
Ages 18–80 · Healthy volunteers
West Park Healthcare Centre · Sites in Canada
Ages 18–85
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 5 · Phase 4 2
First in 2011; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 104 interventional studies indexed under Chronic Cough.
Median enrollment 122 across the 18 interventional studies, 170 across the 4 observational. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Trevi Therapeutics is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Trevi Therapeutics has 2 studies filed under Chronic Cough — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Cough with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05086432McMaster UniversitySputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD | 2027-03 |
| NCT07671924Trevi TherapeuticsThe Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Chronic Cough with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets society guideline-based criteria for a diagnosis of RCC defined as:
Exclusion Criteria:
History of uncontrolled asthma defined as one of the following:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive NAL ER during the titration period, with dose titration starting at 27 milligrams (mg) once daily (QD) and increasing up to 54 mg twice daily (BID) from Day 1 to Day 14. Participants will receive NAL ER 54 mg BID during the fixed-dose treatment period from Day 15 to Day 42.
Drug: NAL ER · Drug: Placebo
Participants will receive NAL ER during the titration period, starting at 27 mg QD to 27 mg BID from Day 1 to Day 14. Participants will receive NAL ER 27 mg BID during the fixed-dose treatment period from Day 15 to Day 42.
Drug: NAL ER · Drug: Placebo
Participants will receive NAL ER 27 mg QD during the titration period from Day 1 to Day 14. Participants will continue to receive NAL ER 27 mg QD during the fixed-dose treatment period from Day 15 to Day 42.
Drug: NAL ER · Drug: Placebo
Participants will receive matching placebo during the titration period from Day 1 to Day 14 and the fixed-dose treatment period from Day 15 to Day 42.
Drug: Placebo
Oral tablets
Also known as: Nalbuphine
Oral tablets
Relative Change From Baseline in 24-hour Cough Frequency at Week 6
Time frame: Baseline, Week 6
Relative Change From Baseline in 24-hour Cough Frequency
Time frame: Baseline up to Week 6
Percentage of Participants Achieving ≥30%, ≥50% and ≥75% Reduction in 24-hour Cough Frequency
Time frame: Baseline up to Week 6
Change From Baseline in Patient Reported Cough Frequency (PR-CF)
Time frame: Baseline up to Week 6
Change From Baseline in Cough Severity Visual Analog Scale (CS-VAS)
Time frame: Baseline up to Week 6
Percentage of Participants Achieving a 30 Millimeter (mm) Improvement in CS-VAS Total Score
Time frame: Baseline up to Week 6
Change From Baseline in Cough Severity Numerical Rating Scale (CS-NRS)
Time frame: Baseline up to Week 6
Change From Baseline in McMaster Cough Severity Questionnaire (MCSQ) Total Score
Time frame: Baseline up to Week 6
Change From Baseline in MCSQ Domains (Intensity and Frequency)
Time frame: Baseline up to Week 6
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 6
Time frame: Baseline, Week 6
Change From Baseline in Each LCQ Domain Score (Physical, Psychological, Social) at Week 6
Time frame: Baseline, Week 6
Percentage of Participants Achieving a 1.3- Point Increase From Baseline in LCQ Total Score at Week 6
Time frame: Baseline, Week 6
Relative Change From Baseline in Awake Cough Frequency
Time frame: Baseline up to Week 6
Relative Change From Baseline in Sleep Cough Frequency
Time frame: Baseline up to Week 6
Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score
Time frame: Baseline up to Week 6
Mean Patient Global Impression of Change for Cough (PGI-C) Cough Score
Time frame: Up to Week 6
Change From Baseline in International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF) Score at Week 6
Time frame: Baseline, Week 6
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to Day 63
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.
Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 15 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine